Alli Oluseun, Booker Oscar, Davies James
Division of Cardiology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Department of Cardiovascular Surgery, University of Alabama at Birmingham, Birmingham, Alabama.
Catheter Cardiovasc Interv. 2016 Jun;87(7):1342-1346. doi: 10.1002/ccd.26040. Epub 2015 May 27.
Transcatheter valve-in-valve (VIV) implantation is emerging as a therapeutic option for treatment of failed bioprosthesis in patients that are deemed high-risk or inoperable for redo-valve replacement. It can be carried out in suitable bioprosthetic valves in any position and usually performed as an elective or semi-elective procedure. Here, we report a case of emergent transcatheter VIV implantation in a failed mitral bioprosthesis in a critically ill patient with cardiogenic shock. We conclude that transcatheter VIV implantation may also be an option for critically ill patients with failing bioprosthesis. © 2015 Wiley Periodicals, Inc.
经导管瓣中瓣(VIV)植入术正逐渐成为一种治疗选择,用于治疗那些被认为具有高风险或无法进行再次瓣膜置换手术的生物假体功能障碍患者。它可以在任何位置的合适生物假体瓣膜中进行,通常作为择期或半择期手术。在此,我们报告一例在一名患有心源性休克的重症患者中,对功能障碍的二尖瓣生物假体进行紧急经导管VIV植入术的病例。我们得出结论,经导管VIV植入术对于生物假体功能障碍的重症患者也可能是一种选择。© 2015威利期刊公司